




A PRACTICAL HANDBOOK ON THE PHARMACOVIGILANCE OF ANTIMALARIAL MEDICINES



A practical
handbook
on the
pharmacovigilance
of antimalarial
medicines



**World Health
Organization**

ISBN 978 92 4 154749 9

© **World Health Organization 2007**

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate borderlines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by WHO Document Production Services, Geneva, Switzerland

Acknowledgements

This publication was developed following two training courses in Zambia and Ghana in 2007. The manuscript was drafted by David Coulter who was responsible for the Intensive Medicines Monitoring Programme in New Zealand and sincere thanks are expressed to him for his dedication. The draft was reviewed by members of the Advisory Committee on the Safety of Medicinal Products.

Art Direction: Jean-Claude Fattier, WHO

Photograph design: Caroline Scudamore, WHO

WHO expresses its sincere appreciation to the European Community for providing financial support to the development of this publication.



A practical handbook on the pharmacovigilance of antimalarial medicines

A. Introduction.....	9
1. Pharmacovigilance	9
Definition	9
Explanation	9
Pharmacovigilance of antimalarials	10
2. Pharmacovigilance centre	10
B. Passive or active pharmacovigilance?	10
1. Passive pharmacovigilance	10
2. Active pharmacovigilance	11
C. Spontaneous reporting	11
1. Introduction	11
1.1. Background	11
1.2. Adverse reactions	11
2. Objectives.....	12
3. Minimum reporting requirements.....	14
4. How to report.....	14
4.1. Reporting form	14
4.2. Other options for reporting.....	15
5. Where to report	15
6. What to report	16
6.1. Essential data elements	16
6.2. Advice to reporters.....	17
6.3. Follow-up when necessary.....	18
7. When to report	18
8. Who should report	18
9. Sharing the results.....	19
9.1. Individual, immediate	19
9.2. Relevant summaries or reviews.....	19
9.3. Regular transmission to the WHO database	20
10. Data entry	20
10.1. Options.....	20
10.2. Vigiflow.....	20
D. Cohort event monitoring.....	21
1. Introduction	21
1.1. Event monitoring	21
1.2. Description	21
1.3. Objectives.....	22
1.4. Selection of drugs to monitor	23

1.5 Basic processes	23
1.6. Programme duration	23
2. The epidemiology	24
2.1. Observational	24
2.2. Prospective	24
2.3. Inceptional	24
2.4. Dynamic	24
2.5. Longitudinal	24
2.6. Descriptive	24
3. First step – implementation	25
4. Second step – establishing the cohort(s)	27
4.1. Numbers of patients	27
4.2. Selection of patients	29
4.3. Patient identification	30
4.4. Other patient data	30
4.5. Background data	30
4.6. Controls or comparators	30
5. Third step – acquiring the data	31
The medicines	31
5.1. Details of administration of antimalarial medicine	31
5.2. Concomitant medicines	31
The events	32
5.3. Principles of event reporting	32
5.4. Reporting requirements	33
5.5. Recording event details	33
5.6. Reporting forms (questionnaires)	33
5.7. Who should report?	34
5.8. Follow-up	35
5.9. Reasons for non-adherence	36
5.10 How and where to send the completed questionnaires	36
5.11 Record linkage	37
6. Database for CEM	38
6.1. Choice of database	38
6.2. Data elements/fields	38
7. Maximizing the reporting rate	40
8. General advice and information	41
8.1. Don't ask for too much	41
8.2. Non-serious events	41
8.3. Be open minded	41
8.4. Privacy	41

9.	Fourth step – clinical review	42
9.1.	The event should be specific to be acceptable for recording	42
9.2.	Determining the event term.....	42
9.3.	Building an events dictionary	45
9.4.	Seriousness	45
9.5.	Severity	45
9.6.	Outcome	46
E.	Data processing.....	46
1.	Data entry	46
1.1.	Requirements	46
1.2.	Standard formats.....	47
2.	Quality control	47
2.1.	Control at entry.....	47
2.2.	Systematic checks	47
3.	Coding of medicines and diseases	48
3.4.	Standardized recording of event details	48
3.5.	Collating and summarizing the events.....	50
F.	Special types of event.....	50
1.	Serious events.....	50
2.	Pregnancies	50
2.1.	Background	51
2.2.	Follow-up.....	52
2.3.	Register.....	52
2.4.	Lactation exposure	53
2.5.	Verification of drug-effect.....	54
3.	Deaths	54
4.	Lack of efficacy.....	54
4.1.	Event terms.....	54
4.2.	Reasons for lack of efficacy	55
4.3.	Recrudescence of malaria	55
5.	Delayed reactions.....	55
6.	Concomitant morbid conditions.....	56
G.	Relationship/causality assessment.....	56
1.	Background	56
1.1.	Two basic questions	56
1.2.	Objective and subjective assessments	56
1.3.	General understanding	57
2.	Factors to consider when assessing the relationship between drug and event	57
2.1.	Did the event begin before the patient commenced taking the medicine?.....	57

2.2. Is there any other possible cause for the event?	57
2.3. Is the duration to onset of the event plausible?	57
2.4. Did the event occur after the commencement of taking some other medicine?	57
2.5. Did the event occur after the onset of some new illness?	57
2.6. What is the response to withdrawal of the medicine (dechallenge)?	57
2.7. What is the response to rechallenge with that medicine only?	57
3. Categories of relationship:	59
4. Requirements for inclusion of an event in a specific category:	60
4.1. Certain	60
4.2. Probable	60
4.3. Possible	61
4.4. Unlikely	62
4.5. Unclassified or conditional	62
4.6. Unassessable	62
5. Processes for establishing the relationship	63
5.1. Result of dechallenge	63
5.2. Result of rechallenge with the same medicine by itself	63
5.3. Outcome of the event	63
5.4. Clinical details	63
5.5. Logic check	64
H. Signal identification	65
1. Introduction	65
1.1. General approach	65
1.2. Definition of a signal	65

预览已结束，完整报告链接

<https://www.yunbaogao.cn/report/index/repo>